Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.

Seminars in vascular medicine - 1 Feb 2004

Wonderling David, Umans-Eckenhausen Marina A W, Marks Dalya, Defesche Joep C, Kastelein John J P, Thorogood Margaret

Abstract excerpt

Familial hypercholesterolemia (FH) is associated with pronounced atherosclerosis leading to premature cardiovascular disease and untimely death. Despite the availability of effective preventative drug treatments, many affected individuals remain undiagnosed and untreated until they become symptomatic with cardiovascular disease. To assess the cost-effectiveness of systematic genetic screening of family members of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coronary Disease
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Infant, Newborn

Share to Netherlands

Share to Quality-Adjusted Life Years

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 15199439
DOI: 10.1055/s-2004-822992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.PMID 15199439Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

Cascade genetic screening for familial hypercholesterolemiaSemantic proximity Read ↗

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls.Semantic proximity Read ↗

[A family-based strategy for diagnosing familial hypercholesterolemia].Semantic proximity Read ↗

Genetic screening by DNA technology: a systematic review of health economic evidence.Semantic proximity Read ↗

Synthesized Economic Evidence on the Cost-effectiveness of Screening Familial Hypercholesterolemia: A meta-analytic review and Aggregate Distributional Cost-Effectiveness AnalysisSemantic proximity Read ↗

Cascade screening for familial hypercholesterolemia: Practical consequences.Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysisSemantic proximity Read ↗

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.Semantic proximity Read ↗

Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of high-cost drugsSemantic proximity Read ↗

Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.